NewsBenzingaBarclays mantiene il giudizio Overweight su Omada Health, abbassa il target di prezzo a 24 dollari Barclays mantiene il giudizio Overweight su Omada Health, abbassa il target di prezzo a 24 dollari Benzinga 2026.10.28 15:48 (GMT+0) Open on Benzinga Other news Nvidia’s $105 Billion OpenAI Bet Has a 20-Year Catch Freedom Broker Upgrades Espey Manufacturing to Buy, Maintains Price Target to $70 QUICK SPARK: Chip Stocks Eye Worst Two-Month Drop Since 2008 Carlyle, Clearlake Bet Big On Sports — And PE Deals Are Surging Target's $301 Million Tariff Windfall 'Flattered' Earnings, Analyst Says Freedom Broker Maintains Buy on SKYX Platforms, Lowers Price Target to $2